Bone densitometry manufacturer Lunar issued a profit warning on Jan. 14, notifying investors that its financial results for the second fiscal quarter (end-December) will be below analysts’ expectations. The Madison, WI, firm said that U.S. sales
Bone densitometry manufacturer Lunar issued a profit warning on Jan. 14, notifying investors that its financial results for the second fiscal quarter (end-December) will be below analysts expectations. The Madison, WI, firm said that U.S. sales have been below the companys targets, and that the firms new Prodigy fan-beam densitometer has not had a chance to impact the companys results. Lunar introduced Prodigy at the RSNA conference last month (see story, page 3).
Lunar expects to report revenues of $23.4 million, an increase of 8% compared with $21.6 million in the same period a year ago. Net income swooned, however: Lunar expects to post a profit of $730,000, compared with net income of $2.7 million in the second quarter of 1998. The news prompted investors to sell Lunars stock, and shares of the company were trading at $9.13 on Jan. 15, a drop of 12%.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.